Clinical Trial Update: A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 2]

View source ↗

Summary

Phase 2 long-term safety study update for BCX9930 in participants with Paroxysmal nocturnal hemoglobinuria. The trial was terminated and results were posted on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• BCX9930 (Factor D inhibitor)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 2 | Status: TERMINATED | Results posted: 2024-12-13